Bora Pharmaceuticals : The Company's stock has reached the announcement criteria several times recently. The below information is published for investor's information
The Company's stock has reached the announcement
criteria several times recently. The below information
is published for investor's information
Date of events
2022/06/22
To which item it meets
paragraph 53
Statement
1.Date of occurrence of the event:2022/06/22
2.Cause of occurrence:In accordance the advise from
Taipei Exchange
3.Financial and business information:
Recent Month May 2022 May 2021 YOY Comparison
Revenue(million) 501.80 424.68 18.16%
Income before tax(million) 140.96 33.12 325.59%
Income after tax(million) 93.13 25.33 267.62%
EPS(dollar) 1.37 0.38 263.72%
Recent 2 Month April-May 2022 April-May 2021 YOY Comparison
Revenue(million) 952.36 838.72 13.55%
Income before tax(million) 222.99 99.53 124.05%
Income after tax(million) 156.83 73.71 112.77%
EPS(dollar) 2.30 1.09 110.51%
Recent Quarter 2022 Q1 2021 Q1 YOY Comparison
Revenue(million) 1,117.25 1,367.06 -18.27%
Income before tax(million) 253.02 452.88 -44.13%
Income after tax(million) 179 334.44 -46.42%
EPS(dollar) 2.62 4.96 -47.18%
Recent 4 Quarter 2021 Q2~2022 Q1
Revenue(million) 4,650.08
Income before tax(million) 824.11
Income after tax(million) 594.47
EPS(dollar) 8.69
4.Any material information that needs to be specified
according to Article 4 of Taipei Exchange Procedures
for Verification and Disclosure of Material Information
of Companies with TPEx Listed Securities:
The Company publishes the material inforamtion in
accordance with the guidance from Taipei Exchange,
for more information, please refer to MOPS
5.Any material information in a press conference listed
under Article 11 of Taipei Exchange Procedures for
Verification and Disclosure of Material Information of
Companies with TPEx Listed Securities:NA
6.Any other matters that need to be specified:
Note:April-May 2022 and April-May 2021 numbers are prepared by the
Company in accordance to IFRS. These number are not audit or review
by the CPA, only for investor's reference.
Note:2022 Q1 number has been reviewed by CPA.
Note:Recent 4 quarter's numbers are prepared by the Company in
accordance to IFRS. These number are not audit by the CPA.
註：以上111年4月及5月及去年同期比較數之財務資料係本公司採IFRS會計準則編製
之合併自結數，未經會計師查核(閱)，僅供投資人參考。
註：最近一季111年第1季係指單季數字，係經會計師核閱。
註：最近四季累計係本公司110年第2季至111年第1季採IFRS編製之合併數，係未經會
計師查核。
Attachments
Original Link
Original Document
Permalink
Disclaimer
Bora Pharmaceuticals Co. Ltd. published this content on 22 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 June 2022 07:24:09 UTC.
Bora Pharmaceuticals Co Ltd is a Taiwan-based company principally engaged in the agency and sales of western medicines, as well as the research, development, manufacture and sales of new drugs and health products. The Company's main products are categorized into prescription drugs and health care products, including central nervous drugs, cardiovascular drugs, antibiotics, antiviral agents, ophthalmic drugs, gastrointestinal drugs, foam ingots and health care products. In addition, the Company has biopharmaceutical technologies related to the development of cell lines for the production of protein drugs, the development and analysis of upstream and downstream processes, as well as the establishment of quality control and testing specifications and the creation of cell banks.
Bora Pharmaceuticals : The Company's stock has reached the announcement criteria several times recently. The below information is published for investor's information
BORA PHARMACEUTICALS CO., LTD. 
